knowledge -WSS

knowledge

author：fashion 2025-09-04 04:43:27 - browse：4

Cheryl Meier had watched clinical trial enrollment announcements for years — but always for her sons’ type 1 diabetes, never for herself. Her OB-GYN had put her on Effexor for her depression 20 years ago, and it worked well enough — she could sleep for the first time in her life, and she no longer cried at every little thing. But it never worked for her dark thoughts.

But then she retired, and then she had time, and then she saw an email — “I guess once your name gets on a list, it’s there,” she said — for an experimental depression drug called zuranolone.

Unlike today’s crowded market of SSRIs, prescribed once and taken for months, years, or even indefinitely, zuranolone, developed by Sage Therapeutics, promises something different.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Study: Hearing aids may slow cognitive decline in those at risk

leisure time

WSS

Flagship, Pfizer team up in deal worth up to $7 billion

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

US soldier in North Korean custody after crossing DMZ line

A Theranos scientist

Readout LOUD podcast: How biotech is using artificial intelligence

Gilead might be held responsible for not developing a drug

entertainment

knowledge

Wikipedia

As demand for Covid shots wanes, Moderna seeks its next success

Britain’s MI6 chief says his spies are using AI to disrupt flow of weapons to Russia

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Key House Republican on health care plans exit from Congress

Cancer drug shortages should be causing more outrage

Twill hunts for pharma partner to market its depression app

Novavax promises a turnaround & Lilly roils the obesity market

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Sports medicine is finally prioritizing gender equality

FDA seeking to stop procedures at two unregulated stem cell clinics

hotspot

What we’ve learned from the Aduhelm mess

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

UK homeowners get some respite as inflation falls by more than anticipated to a 15

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

Manchin plays down potential 3rd

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

leisure time

hotspot

explore

focus